ALN-PCS02 + Sterile Normal Saline (0.9% NaCl)
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Elevated LDL-Cholesterol (LDL-C)
Conditions
Elevated LDL-Cholesterol (LDL-C)
Trial Timeline
Sep 1, 2011 → Sep 1, 2012
NCT ID
NCT01437059About ALN-PCS02 + Sterile Normal Saline (0.9% NaCl)
ALN-PCS02 + Sterile Normal Saline (0.9% NaCl) is a phase 1 stage product being developed by Alnylam Pharmaceuticals for Elevated LDL-Cholesterol (LDL-C). The current trial status is completed. This product is registered under clinical trial identifier NCT01437059. Target conditions include Elevated LDL-Cholesterol (LDL-C).
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01437059 | Phase 1 | Completed |
Competing Products
12 competing products in Elevated LDL-Cholesterol (LDL-C)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Muvalaplin + Placebo | Eli Lilly | Phase 3 | 77 |
| Baricitinib | Eli Lilly | Pre-clinical | 23 |
| Rosuvastatin | AstraZeneca | Phase 3 | 77 |
| TQJ230 + Placebo | Novartis | Phase 3 | 77 |
| LIK066 + Placebo | Novartis | Phase 2 | 52 |
| Olpasiran | Amgen | Phase 1 | 32 |
| Maridebart cafraglutide + Placebo | Amgen | Phase 2 | 51 |
| Ivabradine | Amgen | Phase 3 | 76 |
| ISIS-APO(a)Rx + Placebo | Ionis Pharmaceuticals | Phase 2 | 49 |
| APOC-III-L-Rx + Placebo Comparator | Ionis Pharmaceuticals | Phase 1 | 30 |
| ISIS 681257 + Placebo | Ionis Pharmaceuticals | Phase 2 | 49 |
| IONIS-APO(a)-LRx + Sterile Normal Saline (0.9% NaCl) | Ionis Pharmaceuticals | Phase 1 | 30 |